On April 6, 2021, Lanfan Medical Co., Ltd. announced that it intends to jointly invest with the company's chairman Ms. Liu Wenjing, director Mr. Li Zhenping and vice president Mr. Sun Chuanzhi A total of RMB 172 million participated in the ongoing equity financing of Nanjing Wolfman Medical Technology Co., Ltd. (“Wolfman Medical”).Corresponding to its 16.38% equity after the completion of this round of financing.
at the same time,Shandong Jiwei Medical Products Co., Ltd. (“Jiwei Medical”), a wholly-owned subsidiary of Blue Sail Medical, has served as the director of Wolfman Medical’s intravascular tomography.（Optical Coherence Tomography，OCT）The exclusive distributor of products in mainland China,After this investment, it will promote Jiwei Medical and Wolfman Medical to share the sales network of Cardiology through complementary resources and win-win cooperation, jointly promote the market development of domestic OCT products, and provide patients with more accurate intracavitary imaging. Accurate, scientific and standardized coronary interventional medicine.

　　Founded in 2014, Wolfman Medical is a provider of advanced medical imaging, diagnosis and medical information technology solutions. It has R&D facilities in Nanjing, China, Shanghai and San Francisco, USA. It is committed to innovating interventional cardiovascular and cerebrovascular diagnosis and treatment devices and technologies. 's research and development. This July 2020,We and SAIF Capital jointly made a Series A investment in Wolfman.The core product OCT independently developed by Wolfman Medical was approved for the first time in March 2019, and the single-use intravascular imaging catheter was approved in August 2019.It is a rare start-up company in the cardiovascular field that has obtained two special approvals for innovative medical devices.OCT With its extremely high resolution, it has become one of the most rapidly developing endoluminal imaging methods in optimizing PCI treatment, studying the mechanism of stent thrombosis, evaluating plaque vulnerability, and identifying culprit lesions.